Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ironwood Pharmaceuticals, Inc.
< Previous
1
2
Next >
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
October 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
October 05, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
August 08, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
July 25, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
June 29, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
VECT
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
June 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
VECT
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
June 12, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
May 22, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
May 08, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
May 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
April 24, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
April 20, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
February 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
February 13, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
February 02, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
January 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
November 03, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
October 20, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
September 06, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
September 01, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
August 04, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
July 21, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
May 25, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
May 09, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
May 05, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
April 21, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.